A Second-Look at the Repeat Resections of Bladder Tumors

Madison Lyon, S. White, Taylor A. Goodstein, Madeline Koerner, A. Colvin, C. O’Donnell, Janine L Oliver, Shandra S. Wilson
{"title":"A Second-Look at the Repeat Resections of Bladder Tumors","authors":"Madison Lyon, S. White, Taylor A. Goodstein, Madeline Koerner, A. Colvin, C. O’Donnell, Janine L Oliver, Shandra S. Wilson","doi":"10.14740/WJNU361W","DOIUrl":null,"url":null,"abstract":"Background: Research looking at the effects of repeat transurethral resection of bladder tumor (TURBT) on long-term survival and recurrence of bladder cancer has mixed results, with some studies showing improvement and others showing unclear benefit. The purpose of this current study is to evaluate the differences in recurrence rates, progression, and survival for patients with non-muscle invasive bladder cancer (NMIBC) who underwent a second TURBT 2 - 6 weeks after an initial TURBT, as compared to patients who only had an initial TURBT. Methods: We performed a retrospective analysis of patients who received a TURBT at our institution over a 12-year period (2005 - 2017). Patients 18 years or older with high-grade pT1 or pTis pathology on initial TURBT were included. Patients with low-grade, pTa, or stage pT2 or greater on initial TURBT and patients with variant histology other than urothelial carcinoma were excluded from the study. Differences in overall survival, recurrence rates, and cancer progression were analyzed using Cox regression to event and Poisson regression to number of occurrences in patients who had repeat TURBT vs. those who did not. Cancer progression was measured as time to cystectomy. Results: One hundred fifty-three patients with a diagnosis of high-grade NMIBC were included in the study. Forty-six patients (30.1%) had a repeat TURBT. There was no significant difference in baseline characteristics including age, stage, or gender between the two groups. After a median follow-up of 67.5 months (range 7.5 - 200 months), there was no significant difference in overall survival (OS) (P = 0.63), cancer progression (P = 0.51) or recurrence rates (P = 0.60) for patients who underwent second-look TURBT compared to those who did not. Of those patients who underwent repeat TURBT, 32 (69.6%) had residual tumor and 13 (28.2%) had a change in stage. Of the patients that had a change in stage, five were upstaged to muscle invasive (pT2) disease. Conclusions: Our analysis did not show an association between second-look TURBT with overall survival, progression, or recurrence rate of bladder cancer as compared to no second-look TURBT. However, there was a small rate of upstaging to pT2 disease on repeat TURBT. Even though there was no change in OS, repeat TURBT has an important role in finding T2 disease, and this is so critical that continuing with this conservative approach of a second TURBT is still recommended. World J Nephrol Urol. 2018;7(3-4):63-66 doi: https://doi.org/10.14740/wjnu361w","PeriodicalId":91634,"journal":{"name":"World journal of nephrology and urology","volume":"7 1","pages":"63-66"},"PeriodicalIF":0.0000,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of nephrology and urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14740/WJNU361W","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Research looking at the effects of repeat transurethral resection of bladder tumor (TURBT) on long-term survival and recurrence of bladder cancer has mixed results, with some studies showing improvement and others showing unclear benefit. The purpose of this current study is to evaluate the differences in recurrence rates, progression, and survival for patients with non-muscle invasive bladder cancer (NMIBC) who underwent a second TURBT 2 - 6 weeks after an initial TURBT, as compared to patients who only had an initial TURBT. Methods: We performed a retrospective analysis of patients who received a TURBT at our institution over a 12-year period (2005 - 2017). Patients 18 years or older with high-grade pT1 or pTis pathology on initial TURBT were included. Patients with low-grade, pTa, or stage pT2 or greater on initial TURBT and patients with variant histology other than urothelial carcinoma were excluded from the study. Differences in overall survival, recurrence rates, and cancer progression were analyzed using Cox regression to event and Poisson regression to number of occurrences in patients who had repeat TURBT vs. those who did not. Cancer progression was measured as time to cystectomy. Results: One hundred fifty-three patients with a diagnosis of high-grade NMIBC were included in the study. Forty-six patients (30.1%) had a repeat TURBT. There was no significant difference in baseline characteristics including age, stage, or gender between the two groups. After a median follow-up of 67.5 months (range 7.5 - 200 months), there was no significant difference in overall survival (OS) (P = 0.63), cancer progression (P = 0.51) or recurrence rates (P = 0.60) for patients who underwent second-look TURBT compared to those who did not. Of those patients who underwent repeat TURBT, 32 (69.6%) had residual tumor and 13 (28.2%) had a change in stage. Of the patients that had a change in stage, five were upstaged to muscle invasive (pT2) disease. Conclusions: Our analysis did not show an association between second-look TURBT with overall survival, progression, or recurrence rate of bladder cancer as compared to no second-look TURBT. However, there was a small rate of upstaging to pT2 disease on repeat TURBT. Even though there was no change in OS, repeat TURBT has an important role in finding T2 disease, and this is so critical that continuing with this conservative approach of a second TURBT is still recommended. World J Nephrol Urol. 2018;7(3-4):63-66 doi: https://doi.org/10.14740/wjnu361w
膀胱肿瘤重复切除的再观察
背景:关于反复经尿道膀胱肿瘤切除术(turt)对膀胱癌长期生存和复发影响的研究结果好坏参半,一些研究显示改善,另一些研究显示不明确的益处。本研究的目的是评估非肌肉浸润性膀胱癌(NMIBC)患者在首次TURBT后2 - 6周进行第二次TURBT的复发率、进展和生存的差异,与仅进行首次TURBT的患者相比。方法:我们对我院12年间(2005 - 2017年)接受TURBT的患者进行了回顾性分析。患者年龄≥18岁,初始TURBT时伴有高级别pT1或pTis病理。初始TURBT分级低、pTa或pT2期或以上的患者以及除尿路上皮癌外的其他组织学变异患者被排除在研究之外。使用Cox回归分析重复TURBT患者与未重复TURBT患者的事件和泊松回归分析总生存率、复发率和癌症进展的差异。以切除膀胱的时间衡量肿瘤进展。结果:153例诊断为高级别NMIBC的患者被纳入研究。46例(30.1%)患者有重复TURBT。两组患者的基线特征(包括年龄、分期或性别)无显著差异。在中位随访67.5个月(范围7.5 - 200个月)后,与未接受二次检查TURBT的患者相比,接受二次检查TURBT的患者在总生存期(OS) (P = 0.63)、癌症进展(P = 0.51)或复发率(P = 0.60)方面没有显著差异。在接受重复TURBT的患者中,32例(69.6%)有肿瘤残留,13例(28.2%)有分期改变。在分期改变的患者中,有5例被抢到了肌肉侵袭性(pT2)疾病。结论:我们的分析并未显示与无复查TURBT相比,复查TURBT与膀胱癌的总生存、进展或复发率之间存在关联。然而,重复TURBT中出现pT2疾病的比例较小。尽管OS没有变化,但重复TURBT在发现T2疾病中具有重要作用,这是如此关键,因此仍然建议继续采用这种保守的方法进行第二次TURBT。世界卫生杂志,2018;7(3-4):63-66 doi: https://doi.org/10.14740/wjnu361w
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信